NOD2 and cancer: For NOD2 rs2066847/rs5743293 (3020insC) polymorphism, carriers of insC/insC or insC/− genotype were associated with increased cancer risk compared with wild-type −/− carriers, respectively (insC/insC vs. −/−: OR = 3.42, 95% CI = 1.59–7.40, P = 0.002; insC/− vs. −/−: OR = 1.35, 95% CI = 1.06–1.72, P = 0.016).